Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 32

1.

Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.

Xing D, Suryo Rahmanto Y, Zeppernick F, Hannibal CG, Kjaer SK, Vang R, Shih IM, Wang TL.

Hum Pathol. 2017 Oct;68:87-91. doi: 10.1016/j.humpath.2017.08.021. Epub 2017 Sep 2.

PMID:
28873354
2.

Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion.

Xin X, Gu Y, Chen Y, Huang Y, Mo Z, Hu Y.

Oncotarget. 2017 May 16;8(20):33745-33755. doi: 10.18632/oncotarget.16807.

3.

A Systems Biology Comparison of Ovarian Cancers Implicates Putative Somatic Driver Mutations through Protein-Protein Interaction Models.

Yang MQ, Elnitski L.

PLoS One. 2016 Oct 27;11(10):e0163353. doi: 10.1371/journal.pone.0163353. eCollection 2016.

4.

Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas.

Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S.

J Pathol Clin Res. 2014 Nov 5;1(1):41-53. doi: 10.1002/cjp2.4. eCollection 2015 Jan.

5.

Epithelial ovarian cancer: the molecular genetics of epithelial ovarian cancer.

Krzystyniak J, Ceppi L, Dizon DS, Birrer MJ.

Ann Oncol. 2016 Apr;27 Suppl 1:i4-i10. doi: 10.1093/annonc/mdw083. Review.

6.

The molecular pathology of ovarian serous borderline tumors.

Malpica A, Wong KK.

Ann Oncol. 2016 Apr;27 Suppl 1:i16-i19. doi: 10.1093/annonc/mdw089.

7.

p53 downregulates the Fanconi anaemia DNA repair pathway.

Jaber S, Toufektchan E, Lejour V, Bardot B, Toledo F.

Nat Commun. 2016 Apr 1;7:11091. doi: 10.1038/ncomms11091.

8.

The oncogenic triangle of HMGA2, LIN28B and IGF2BP1 antagonizes tumor-suppressive actions of the let-7 family.

Busch B, Bley N, Müller S, Glaß M, Misiak D, Lederer M, Vetter M, Strauß HG, Thomssen C, Hüttelmaier S.

Nucleic Acids Res. 2016 May 5;44(8):3845-64. doi: 10.1093/nar/gkw099. Epub 2016 Feb 24.

9.

Cyclin G2 inhibits epithelial-to-mesenchymal transition by disrupting Wnt/β-catenin signaling.

Bernaudo S, Salem M, Qi X, Zhou W, Zhang C, Yang W, Rosman D, Deng Z, Ye G, Yang B, Vanderhyden B, Wu Z, Peng C.

Oncogene. 2016 Sep 8;35(36):4816-27. doi: 10.1038/onc.2016.15. Epub 2016 Feb 15.

10.

The status of epidermal growth factor receptor in borderline ovarian tumours.

Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, Sriraksa R, El-Kaffash D, El-Etreby N, Natrajan R, Foroni L, Osborne R, El-Bahrawy M.

Oncotarget. 2016 Mar 1;7(9):10568-77. doi: 10.18632/oncotarget.7257.

11.

Distinct lymphocyte antigens 6 (Ly6) family members Ly6D, Ly6E, Ly6K and Ly6H drive tumorigenesis and clinical outcome.

Luo L, McGarvey P, Madhavan S, Kumar R, Gusev Y, Upadhyay G.

Oncotarget. 2016 Mar 8;7(10):11165-93. doi: 10.18632/oncotarget.7163.

12.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Hunter SM, Anglesio MS, Ryland GL, Sharma R, Chiew YE, Rowley SM, Doyle MA, Li J, Gilks CB, Moss P, Allan PE, Stephens AN, Huntsman DG, deFazio A, Bowtell DD; Australian Ovarian Cancer Study Group, Gorringe KL, Campbell IG.

Oncotarget. 2015 Nov 10;6(35):37663-77. doi: 10.18632/oncotarget.5438.

13.

Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.

BMC Cancer. 2015 May 19;15:415. doi: 10.1186/s12885-015-1421-8.

15.

Label-free LC-MSe in tissue and serum reveals protein networks underlying differences between benign and malignant serous ovarian tumors.

Wegdam W, Argmann CA, Kramer G, Vissers JP, Buist MR, Kenter GG, Aerts JM, Meijer D, Moerland PD.

PLoS One. 2014 Sep 29;9(9):e108046. doi: 10.1371/journal.pone.0108046. eCollection 2014.

16.

Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.

Jönsson JM, Johansson I, Dominguez-Valentin M, Kimbung S, Jönsson M, Bonde JH, Kannisto P, Måsbäck A, Malander S, Nilbert M, Hedenfalk I.

PLoS One. 2014 Sep 16;9(9):e107643. doi: 10.1371/journal.pone.0107643. eCollection 2014.

17.

The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.

Hua KT, Wang MY, Chen MW, Wei LH, Chen CK, Ko CH, Jeng YM, Sung PL, Jan YH, Hsiao M, Kuo ML, Yen ML.

Mol Cancer. 2014 Aug 12;13:189. doi: 10.1186/1476-4598-13-189.

18.

Roles of neutrophil gelatinase-associated lipocalin (NGAL) in human cancer.

Candido S, Maestro R, Polesel J, Catania A, Maira F, Signorelli SS, McCubrey JA, Libra M.

Oncotarget. 2014 Mar 30;5(6):1576-94.

19.
20.

Ovarian cancer: genomic analysis.

Wei W, Dizon D, Vathipadiekal V, Birrer MJ.

Ann Oncol. 2013 Dec;24 Suppl 10:x7-15. doi: 10.1093/annonc/mdt462. Review.

Supplemental Content

Support Center